{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T19:15:23Z","timestamp":1784315723194,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ando.2018.11.006","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:42:44Z","timestamp":1548808964000},"page":"250-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma"],"prefix":"10.1016","volume":"80","author":[{"given":"Antoine-Guy","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Fraissinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2018.11.006_bib0380","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0385","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ando.2008.09.003","article-title":"Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus","volume":"69","author":"Tabarin","year":"2008","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2018.11.006_bib0390","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1530\/EJE-10-1147","article-title":"AME position statement on adrenal incidentaloma","volume":"164","author":"Terzolo","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4158\/EP.15.5.450","article-title":"American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2018.11.006_bib0400","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7326\/0003-4819-138-5-200303040-00013","article-title":"Management of the clinically inapparent adrenal mass (\u201cincidentaloma\u201d)","volume":"138","author":"Grumbach","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2018.11.006_bib0405","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/er.2002-0031","article-title":"The clinically inapparent adrenal mass: update in diagnosis and management","volume":"25","author":"Mansmann","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2018.11.006_bib0410","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/eje.0.1490273","article-title":"Prevalence and natural history of adrenal incidentalomas","volume":"149","author":"Barzon","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0415","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF03344099","article-title":"Prevalence of adrenal incidentaloma in a contemporary computerized tomography series","volume":"29","author":"Bovio","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2018.11.006_bib0420","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0425","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0430","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","article-title":"Laboratory evaluation of pheochromocytoma and paraganglioma","volume":"60","author":"Eisenhofer","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2018.11.006_bib0435","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2018.11.006_bib0440","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.clinbiochem.2016.05.008","article-title":"Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas","volume":"49","author":"Patin","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ando.2018.11.006_bib0445","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1210\/jc.2009-0303","article-title":"Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors","volume":"94","author":"De Jong","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0450","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/cen.12327","article-title":"Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions","volume":"80","author":"D\u00e4rr","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0455","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1373\/clinchem.2006.076489","article-title":"Is supine rest necessary before blood sampling for plasma metanephrines?","volume":"53","author":"Lenders","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2018.11.006_bib0460","doi-asserted-by":"crossref","first-page":"R87","DOI":"10.1530\/EC-17-0071","article-title":"Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations","volume":"6","author":"Corcuff","year":"2017","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2018.11.006_bib0465","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/cen.12745","article-title":"Diagnosing phaeochromocytoma\/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging","volume":"83","author":"Amar","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-5-1","article-title":"Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age?","volume":"5","author":"Sawka","year":"2005","journal-title":"BMC Endocrine Disorders"},{"key":"10.1016\/j.ando.2018.11.006_bib0475","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","article-title":"Update on modern management of pheochromocytoma and paraganglioma","volume":"32","author":"Lenders","year":"2017","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0480","first-page":"7","article-title":"Le diagnostic biologique de ph\u00e9ochromocytome en 2014","volume":"72","author":"Rouaix-Emery","year":"2014","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.ando.2018.11.006_bib0485","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc1101502","article-title":"Drugs and pheochromocytoma--don\u2019t be fooled by every elevated metanephrine","volume":"364","author":"Neary","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2018.11.006_bib0490","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0495","first-page":"149","article-title":"Les pseudo-ph\u00e9ochromocytomes m\u00e9dicamenteux","volume":"4","author":"Lefebvre","year":"2002","journal-title":"Med Therap\/Endocr"},{"key":"10.1016\/j.ando.2018.11.006_bib0500","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.beem.2013.06.004","article-title":"Determination of catecholamines in plasma and urine","volume":"27","author":"Grouzmann","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0505","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cca.2010.01.012","article-title":"Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma","volume":"411","author":"Peaston","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ando.2018.11.006_bib0510","first-page":"76","article-title":"Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine","volume":"138","author":"D\u00e4rr","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ando.2018.11.006_bib0515","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jc.2007-1354","article-title":"Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma","volume":"93","author":"Algeciras-Schimnich","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0520","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1245\/s10434-007-9776-y","article-title":"The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma","volume":"15","author":"Greenblatt","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2018.11.006_bib0525","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1210\/jc.2013-1844","article-title":"Normotensive incidentally discovered pheochromocytomas display specific biochemical, cellular, and molecular characteristics","volume":"98","author":"Haissaguerre","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0530","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection. diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0535","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ando.2016.02.003","article-title":"SFE\/SFHTA\/AFCE Consensus on Primary Aldosteronism, part 2: first diagnostic steps","volume":"77","author":"Douillard","year":"2016","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0540","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0545","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/HYPERTENSIONAHA.109.139832","article-title":"Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism","volume":"55","author":"Rossi","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ando.2018.11.006_bib0550","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0031-1295460","article-title":"Factors affecting the aldosterone\/renin ratio","volume":"44","author":"Stowasser","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ando.2018.11.006_bib0555","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2016-1963","article-title":"Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism","volume":"101","author":"Baudrand","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0560","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ancard.2015.04.017","article-title":"Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension","volume":"64","author":"Barigou","year":"2015","journal-title":"Ann Cardiol Angeiol"},{"key":"10.1016\/j.ando.2018.11.006_bib0565","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","article-title":"Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment","volume":"29","author":"Wu","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.ando.2018.11.006_bib0570","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jhh.2015.21","article-title":"Potential effects of age on screening for primary aldosteronism","volume":"30","author":"Luo","year":"2016","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ando.2018.11.006_bib0575","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1210\/jc.2010-2918","article-title":"Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0580","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1210\/jc.2016-3851","article-title":"Effect of combined hormonal replacement therapy on the aldosterone\/renin ratio in postmenopausal women","volume":"102","author":"Ahmed","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0585","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.clinbiochem.2012.06.025","article-title":"Progestin-dependent effect of oral contraceptives on plasma aldosterone\/renin ratio","volume":"45","author":"Locsei","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ando.2018.11.006_bib0590","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jchromb.2014.08.042","article-title":"Enhancement of specificity of aldosterone measurement in human serum and plasma using 2D-LC-MS\/MS and comparison with commercial immunoassays","volume":"970","author":"Ray","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ando.2018.11.006_bib0595","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/000456328101800111","article-title":"Interference by polar metabolites in a direct radioimmunoassay for plasma aldosterone","volume":"18","author":"Jones","year":"1981","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.ando.2018.11.006_bib0600","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1373\/clinchem.2016.255737","article-title":"Overestimation of aldosterone by immunoassay in renal impairment","volume":"62","author":"Lam","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2018.11.006_bib0605","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1373\/clinchem.2008.118000","article-title":"Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement","volume":"55","author":"Campbell","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2018.11.006_bib0610","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/0004563216645364","article-title":"2016 Endocrine Society guidelines update for the diagnosis of primary aldosteronism: are the proposed aldosterone-to-renin ratio cut-off values relevant in the era of fully automated immunoassays?","volume":"53","author":"Denimal","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.ando.2018.11.006_bib0615","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of cushing's syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0620","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3803\/EnM.2018.33.2.139","article-title":"Recent updates on the diagnosis and management of cushing's syndrome","volume":"33","author":"Nieman","year":"2018","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0625","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1530\/eje.0.1460231","article-title":"Cortisol binding globulin is important in the interpretation of dynamic tests of the hypothalamic pituitary adrenal axis","volume":"146","author":"Dhillo","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0630","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1210\/jc.2006-1791","article-title":"Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents","volume":"92","author":"Klose","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0635","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ando.2018.04.017","article-title":"The difficulties of pseudo-Cushing's syndrome (or \u00ab\u00a0non-neoplastic hypercortisolism\u00a0\u00bb)","volume":"79","author":"Chabre","year":"2018","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0640","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2265.1982.tb00733.x","article-title":"Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone","volume":"16","author":"Meikle","year":"1982","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0645","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1373\/clinchem.2003.029934","article-title":"Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment","volume":"50","author":"Chan","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2018.11.006_bib0650","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/ncpendmet0837","article-title":"Late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome","volume":"4","author":"Carroll","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0655","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archpsyc.1985.01790320069009","article-title":"Pituitary-adrenal axis rhythm disturbances in psychiatric depression","volume":"42","author":"Pfohl","year":"1985","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ando.2018.11.006_bib0660","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2006-2155","article-title":"The relationship between smoking status and cortisol secretion","volume":"92","author":"Badrick","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0665","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2265.2005.02395.x","article-title":"Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans","volume":"63","author":"Liu","year":"2005","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0670","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cca.2015.10.004","article-title":"Salivary cortisol and cortisone by LC-MS\/MS: validation, reference intervals and diagnostic accuracy in Cushing's syndrome","volume":"451","author":"Antonelli","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ando.2018.11.006_bib0675","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2003-030234","article-title":"Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography","volume":"88","author":"Meikle","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0680","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1373\/clinchem.2016.255034","article-title":"Serum Cortisol: An Up-To-Date Assessment of Routine Assay Performance","volume":"62","author":"Hawley","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2018.11.006_bib0685","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"joint working group of ESES and ENSAT. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"10.1016\/j.ando.2018.11.006_bib0690","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MED.0000000000000333","article-title":"Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling","volume":"24","author":"Bancos","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ando.2018.11.006_bib0695","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0700","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ando.2017.10.005","article-title":"Group 2: Adrenal insufficiency: screening methods and confirmation of diagnosis","volume":"78","author":"Chanson","year":"2017","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0705","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1210\/jc.2002-021897","article-title":"Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease","volume":"88","author":"Schmidt","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0710","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ando.2016.05.002","article-title":"Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics Elecsys\u00ae Cortisol II assay","volume":"77","author":"Raverot","year":"2016","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0715","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1515\/cclm-2016-0400","article-title":"Multicenter performance evaluation of a second generation cortisol assay","volume":"55","author":"Vogeser","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ando.2018.11.006_bib0720","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2018.11.006_bib0725","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2018.11.006_bib0730","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0735","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2018.07.002","article-title":"Expert opinions on adrenal complications in immunotherapy","author":"Haissaguerre","year":"2018","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2018.11.006_bib0745","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1210\/jc.2010-2395","article-title":"A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum","volume":"96","author":"Jung","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2018.11.006_bib0750","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cen.12097","article-title":"What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy?","volume":"78","author":"Lebbe","year":"2013","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426619300216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426619300216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:52:05Z","timestamp":1757717525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426619300216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0003426619300216"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2018.11.006","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}